As part of our process, we perform a rigorous discounted cash-flow methodology that dives into the true intrinsic worth of companies. In Pfizer's (NYSE:PFE) case, we think the firm is worth about $30 per share, a whopping 60% higher than where it is currently trading. This is one of the largest fair value discrepancies that we've seen within our coverage universe. Our full reports on Pfizer and hundreds of other companies are available on our website.

We think a comprehensive analysis of a firm's discounted cash-flow valuation, relative valuation versus industry peers, as well as an assessment of technical and momentum indicators is the best way to identify the most attractive stocks at the best time to buy. This process culminates in what we call our Valuentum Buying Index, which ranks stocks on a scale from 1 to 10, with 10 being the best.

If a company is undervalued both on a DCF and on a relative valuation basis and is showing improvement in technical and momentum indicators, it scores high on our scale. We think our methodology and broad coverage universe is largely responsible for the meaningful outperformance of the portfolio in our Best Ideas Newsletter.

With every company in our coverage universe, we rate them on 13 unique measures. To get started, we show Pfizer's below:

**Investment Highlights**

Though revenue is under pressure, we think the market is severely underestimating Pfizer's long-term opportunity within emerging markets. Total revenue is expanding at a double-digit page in these faster-growing markets, a pace we expect will continue for some time.

Pfizer earns a ValueCreationâ˘ rating of EXCELLENT, the highest possible mark on our scale. The firm has been generating economic value for shareholders for the past few years, a track record we view very positively. Return on invested capital excluding goodwill) has averaged 27.5% during the past three years.

Pfizer's valuation is compelling at this time. The firm is trading at a nice discount to our estimate of its fair value, even after considering an appropriate margin of safety. The firm's forward earnings multiple and PEG ratio also look attractive versus peers. We expect the company to hit the high end of its guidance range for earnings-per-share this year, at $2.26 (by extension, it's trading at about 8 times this year's earnings -- not too shabby).

Pfizer has a good combination of strong free cash flow generation and manageable financial leverage. We expect the firm's free cash flow margin to average about 39.9% in coming years. Total debt-to-EBITDA was 1.7 last year, while debt-to-book capitalization stood at 33.4%.

The firm's share price performance has been roughly in line with that of the market during the past quarter. We'd expect the firm's stock price to converge to our fair value estimate within the next three years, if our forecasts prove accurate.

Pfizer sports a very nice dividend yield of 4.4%. We expect the firm to pay out about 35% of next year's earnings to shareholders as dividends.

**Economic Profit Analysis**

The best measure of a firm's ability to create value for shareholders is expressed by comparing its return on invested capital (ROIC) with its weighted average cost of capital (WACC). The gap or difference between ROIC and WACC is called the firm's economic profit spread. Pfizer's 3-year historical return on invested capital (without goodwill) is 27.5%, which is above the estimate of its cost of capital of 9.5%. As such, we assign the firm a ValueCreationâ˘ rating of EXCELLENT. In the chart to the right, we show the probable path of ROIC in the years ahead based on the estimated volatility of key drivers behind the measure. The solid grey line reflects the most likely outcome, in our opinion, and represents the scenario that results in our fair value estimate.

*(Click to enlarge)*

**Cash Flow Analysis**

Valuation Analysis

** **

We think Pfizer is worth $30 per share, which represents a price-to-earnings (P/E) ratio of about 29.3 times last year's earnings and an implied EV/EBITDA multiple of about 10.3 times last year's EBITDA. Our model reflects a compound annual revenue growth rate of -1.9% during the next five years, a pace that is lower than the firm's 3-year historical compound annual growth rate of 11.9%. Our model reflects a 5-year projected average operating margin of 34.9%, which is above Pfizer 's trailing 3-year average. Beyond year 5, our valuation model assumes free cash flow will grow at an annual rate of -1.1% for the next 15 years and 3% in perpetuity. For Pfizer, our model uses a 9.5% weighted average cost of capital to discount future free cash flows.

*(Click to enlarge)*

**Margin of Safety Analysis**

** **

Our discounted cash flow process values each firm on the basis of the present value of all future free cash flows. Although we estimate the firm's fair value at about $30 per share, every company has a range of probable fair values that's created by the uncertainty of key valuation drivers (like future revenue or earnings, for example). After all, if the future was known with certainty, we wouldn't see much volatility in the markets as stocks would trade precisely at their known fair values. Our ValueRiskâ˘ rating sets the margin of safety or the fair value range we assign to each stock. In the graph above, we show this probable range of fair values for Pfizer . We think the firm is attractive below $23 per share (the green line), but quite expensive above $38 per share (the red line). The prices that fall along the yellow line, which includes our fair value estimate, represent a reasonable valuation for the firm, in our opinion.

**Future Path of Fair Value **

** **

We estimate Pfizer's fair value at this point in time to be about $30 per share. As time passes, however, companies generate cash flow and pay out cash to shareholders in the form of dividends. The chart to the right compares the firm's current share price with the path of Pfizer's expected equity value per share over the next three years, assuming our long-term projections prove accurate. The range between the resulting downside fair value and upside fair value in Year 3 represents our best estimate of the value of the firm's shares three years hence. This range of potential outcomes is also subject to change over time, should our views on the firm's future cash flow potential change. The expected fair value of $37 per share in Year 3 represents our existing fair value per share of $30 increased at an annual rate of the firm's cost of equity less its dividend yield. The upside and downside ranges are derived in the same way, but from the upper and lower bounds of our fair value estimate range.

All told, we're big fans of Pfizer's valuation and would look to add the firm to our Best Ideas Newsletter on any meaningful pullback.

**Disclosure: **I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.